

Asmaa Ibrahim Gomaa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2096273/publications.pdf>

Version: 2024-02-01

33
papers

1,933
citations

471509

17
h-index

454955

30
g-index

33
all docs

33
docs citations

33
times ranked

3432
citing authors

#	ARTICLE	IF	CITATIONS
1	Optimised systematic review tool: Application to candidate biomarkers for the diagnosis of hepatocellular carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, , .	2.5	1
2	Outcomes of curative liver resection for hepatocellular carcinoma in patients with cirrhosis. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 424-439.	2.0	6
3	Decreased Incidence of Hepatocellular Carcinoma after Directly Acting Antiviral Therapy in Patients with Hepatitis C-Related Advanced Fibrosis and Cirrhosis. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 925-935.	3.7	4
4	Prevalence and predictors of post-liver transplantation metabolic bone diseases. <i>Clinical and Experimental Hepatology</i> , 2021, 7, 286-292.	1.3	0
5	Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach. <i>Hepatology</i> , 2020, 72, 198-212.	7.3	92
6	GES: A validated simple score to predict the risk of HCC in patients with HCV-associated advanced liver fibrosis after oral antivirals. <i>Liver International</i> , 2020, 40, 2828-2833.	3.9	31
7	Platelet-albumin-bilirubin score - a predictor of outcome of acute variceal bleeding in patients with cirrhosis. <i>World Journal of Hepatology</i> , 2020, 12, 99-107.	2.0	15
8	<p>Intermediate stage hepatocellular carcinoma: a summary review</p>. <i>Journal of Hepatocellular Carcinoma</i> , 2019, Volume 6, 105-117.	3.7	21
9	Validation of modified albumin-bilirubin-TNM score as a prognostic model to evaluate patients with hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2019, 11, 542-552.	2.0	18
10	Determinants of survival following hepatocellular carcinoma in Egyptian patients with untreated chronic HCV infection in the pre-DAA era. <i>Arab Journal of Gastroenterology</i> , 2018, 19, 26-32.	0.9	9
11	Aiming at the Global Elimination of Viral Hepatitis: Challenges Along the Care Continuum. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofx252.	0.9	22
12	Effectiveness of ravidasvir plus sofosbuvir in interferon-naïve and treated patients with chronic hepatitis C genotype-4. <i>Journal of Hepatology</i> , 2018, 68, 53-62.	3.7	17
13	Health: redefined. <i>Pan African Medical Journal</i> , 2018, 30, 292.	0.8	18
14	The Role of Monocyte/Macrophage and CXCR3 in Differentiation between Recurrent Hepatitis C and Acute Cellular Rejection Postliver Transplantation. <i>Journal of Immunology Research</i> , 2018, 2018, 1-7.	2.2	8
15	Hepatitis C in Egypt – past, present, and future. <i>International Journal of General Medicine</i> , 2017, Volume 10, 1-6.	1.8	130
16	Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion. <i>British Journal of Cancer</i> , 2017, 116, 448-454.	6.4	66
17	The Plasma and Serum Metabotyping of Hepatocellular Carcinoma in a Nigerian and Egyptian Cohort using Proton Nuclear Magnetic Resonance Spectroscopy. <i>Journal of Clinical and Experimental Hepatology</i> , 2017, 7, 83-92.	0.9	4
18	MiR-615-5p depresses natural killer cells cytotoxicity through repressing IGF-1R in hepatocellular carcinoma patients. <i>Growth Factors</i> , 2017, 35, 76-87.	1.7	40

#	ARTICLE	IF	CITATIONS
19	Hepatitis C treatment: where are we now?. International Journal of General Medicine, 2017, Volume 10, 39-52.	1.8	86
20	The Diagnostic Impact of C4d, CD68, and NF- κ B Expression in the Differentiation Between Recurrent Hepatitis C and Acute Cellular Rejection After Liver Transplantation. Applied Immunohistochemistry and Molecular Morphology, 2016, 24, 639-647.	1.2	5
21	Contradicting interplay between insulin-like growth factor-1 and miR-486-5p in primary NK cells and hepatoma cell lines with a contemporary inhibitory impact on HCC tumor progression. Growth Factors, 2016, 34, 128-140.	1.7	49
22	Enhancing NK cell cytotoxicity by miR-182 in hepatocellular carcinoma. Human Immunology, 2016, 77, 667-673.	2.4	44
23	Ascites and alpha-fetoprotein improve prognostic performance of Barcelona Clinic Liver Cancer staging. World Journal of Gastroenterology, 2015, 21, 5654.	3.3	9
24	Utility and cost-effectiveness of screening for hepatocellular carcinoma in a resource-limited setting. Medical Oncology, 2015, 32, 432.	2.5	19
25	Recent advances in multidisciplinary management of hepatocellular carcinoma. World Journal of Hepatology, 2015, 7, 673.	2.0	77
26	Real Life Treatment of Hepatocellular Carcinoma: Impact of Deviation from Guidelines for Recommended Therapy. Asian Pacific Journal of Cancer Prevention, 2015, 16, 6929-6934.	1.2	4
27	Comparing Staging Systems for Predicting Prognosis and Survival in Patients with Hepatocellular Carcinoma in Egypt. PLoS ONE, 2014, 9, e90929.	2.5	61
28	Expression of SSX-1 and SSX-5 genes in the peripheral blood of patients with hepatocellular carcinoma. Egyptian Journal of Medical Human Genetics, 2014, 15, 45-51.	1.0	0
29	Fluorescence in-situ hybridization as a novel technique for rapid and sensitive detection of ascitic fluid infection. Egyptian Liver Journal, 2012, 2, 113-121.	0.6	0
30	Urinary Metabolic Biomarkers of Hepatocellular Carcinoma in an Egyptian Population: A Validation Study. Journal of Proteome Research, 2011, 10, 1828-1836.	3.7	88
31	Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Review of Gastroenterology and Hepatology, 2009, 3, 353-367.	3.0	259
32	Diagnosis of hepatocellular carcinoma. World Journal of Gastroenterology, 2009, 15, 1301.	3.3	140
33	Hepatocellular carcinoma: Epidemiology, risk factors and pathogenesis. World Journal of Gastroenterology, 2008, 14, 4300.	3.3	590